Endocrinology and Metabolism

Original Article

Diabetes, obesity and metabolism
Tirzepatide and Cancer Risk in Individuals with and without Diabetes: A Systematic Review and Meta-Analysis: A.B.M. Kamrul-Hasan, Muhammad Shah Alam, Deep Dutta, Thanikai Sasikanth, Fatema Tuz Zahura Aalpona, Lakshmi Nagendra; Endocrinol Metab. 2025;40(1):112-124. Published online January 15, 2025; DOI: https://doi.org/10.3803/EnM.2024.2164

84,802 View
841 Download
18 Web of Science
23 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Data on the carcinogenic potential of tirzepatide from randomized controlled trials (RCTs) are limited. Furthermore, no meta-analysis has included all relevant RCTs to assess the cancer risk associated with tirzepatide.
Methods
RCTs involving patients receiving tirzepatide in the intervention arm and either a placebo or any active comparator in the control arm were searched through electronic databases. The primary outcome was the overall risk of any cancer, and secondary outcomes were the risks of specific types of cancer in the tirzepatide versus the control groups.
Results
Thirteen RCTs with 13,761 participants were analyzed. Over 26 to 72 weeks, the tirzepatide and pooled control groups had identical risks of any cancer (risk ratio, 0.78; 95% confidence interval, 0.53 to 1.16; P=0.22). The two groups had comparable cancer risks in patients with and without diabetes. In subgroup analyses, the risks were also similar in the tirzepatide versus placebo, insulin, and glucagon-like peptide-1 receptor agonist groups. The overall cancer risk was also comparable for different doses of tirzepatide compared to the control groups; only a 10-mg tirzepatide dose had a lower risk of any cancer than placebo. Furthermore, compared to the control groups (pooled or separately), tirzepatide did not increase the risk of any specific cancer types. Despite greater increments in serum calcitonin with 10- and 15-mg tirzepatide doses than with placebo, the included RCTs reported no cases of papillary thyroid carcinoma.
Conclusion
Tirzepatide use in RCTs over 26 to 72 weeks did not increase overall or specific cancer risk.

Citations

Citations to this article as recorded by

The efficacy and safety of dual GIP/GLP1 receptor agonists (tirzepatide) in diabetes and obesity: a systematic review and network meta-analysis
Karolina Hoffmann, Michał Michalak, Manfredi Rizzo, Viviana Maggio, Anna Paczkowska
Expert Opinion on Drug Safety.2026; 25(6): 1031. CrossRef
Tirzepatide and Obesity: A Narrative Review
Arya Singh, Rahnuma Ahmad, Kona Chowdhury, Mahendra Narwaria, Mainul Haque
Advances in Human Biology.2026; 16(2): 290. CrossRef
Tirzepatide and Cardiovascular Outcomes: A Narrative Review of Mechanisms, Efficacy and Implications for Heart Failure Management
Hamza A. Abdul‐Hafez, Ameer Awashra, Sosana Bdir, Sarah Saife, Qasem Salah, Mohammed Barbarawi, Thabet Swaileh, Ahmed Emara, Mohamed S. Elgendy, Abdalhakim Shubietah
Endocrinology, Diabetes & Metabolism.2026;[Epub] CrossRef
Glucagon-like peptide 1 receptor agonists and cancer risk: the good, the bad and the unknown
Edoardo Mannucci, Ilaria Dicembrini
Nature Reviews Clinical Oncology.2026; 23(6): 459. CrossRef
Incretin-Based Therapy and Thyroid Cancer Risk: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Naseem Eisa, Omar Barood
AACE Endocrinology and Diabetes.2026; 13(3): 400. CrossRef
GLP-1/GIP agonists and cancer: mechanisms, evidence, and nutrition implications
Sedat Arslan, Ayca Aydin
Academia Oncology.2026;[Epub] CrossRef
From diabetes to tumor growth: unravelling the impact of glucose-lowering therapies
R. Modica, A. Liccardi, V. Zamponi, A. Gagliardi, A. Nistor, G. Veroi, A. Arecco, A. Faggiano, A. Colao
Endocrine.2026;[Epub] CrossRef
Short-term effect of tirzepatide on serum calcitonin in adults with obesity
Nikolaos Angelopoulos, George Simeakis, Ioannis Androulakis, Andreas Rizoulis, Anastasios Boniakos, Paraskevi Mentzelopoulou, Areti Korakovouni, Dimitra Zianni, Valentina Petkova, Sarantis Livadas, Rodis Paparodis
Endocrine.2026;[Epub] CrossRef
Insulin Resistance as a Systemic Metabolic Risk State for Cancer: Mechanisms, Biomarkers, and Prevention
Marijana Matek Sarić, Nataša Lisica Šikić, Tamara Sorić, Ana Sarić, Andrija Ivanišin, Ivona Brodić, Mirta Milić
International Journal of Molecular Sciences.2026; 27(12): 5495. CrossRef
A literature review of GLP-1 agonists for the urologist: What do we know so far?
Anayat Ullah, Aliya Ali, Leena Medani, Jack Donati-Bourne
Journal of Clinical Urology.2026;[Epub] CrossRef
Clinical Implications of Mounjaro (Tirzepatide) for Breast Cancer Detection and Management: A Narrative Review
Raafat Mady, Habib Tafazal, Haitham Soliman, Ayman Ramadan, Mohamed Hajaj
Cureus.2026;[Epub] CrossRef
Role of GLP-1 receptor agonists in the prevention and treatment of obesity-related cancer
Giovanna Muscogiuri, Guendalina Del Vecchio, Luca Colangeli, Valeria Guglielmi, Paolo Sbraccia, Annamaria Colao
Internal and Emergency Medicine.2026;[Epub] CrossRef
Metabolism in PTEN hamartoma tumour syndrome
Phil Ambery, Ralph Bågenholm, Thomas Pepper, Claire M. Barton, Maria A. Whitehead, Lewis H. Rodriguez, Peter J. Greasley
Metabologia.2026;[Epub] CrossRef
Dietary and pharmacological energy restriction and exercise for healthspan extension
Maria Lastra Cagigas, Isabella De Ciutiis, Andrius Masedunskas, Luigi Fontana
Trends in Endocrinology & Metabolism.2025; 36(6): 521. CrossRef
GLP-1 receptor agonists in the context of cancer: the road ahead
Isabelle R. Miousse
American Journal of Physiology-Cell Physiology.2025; 328(6): C1822. CrossRef
Treatment of type 2 diabetes mellitus - a current view of the different drug classes and strategies for their use
Jan Brož
Vnitřní lékařství.2025; 71(3): 144. CrossRef
Repurposing glucose-lowering drugs for cancer therapy
Michaela Luconi, Giulia Cantini, Clara Crescioli
Trends in Cancer.2025; 11(7): 691. CrossRef
Impact of 1-Year Tirzepatide Use on Glycemic and Metabolic Profile in Overweight to Obese People with Type 1 Diabetes: A Systematic Review and Meta-Analysis
Deep Dutta, Abul Bashar Mohammad Kamrul-Hasan, Ritin Mohindra, Nishant Raizada
Diabetes Technology and Obesity Medicine.2025;[Epub] CrossRef
Obesity and Pancreatic Diseases: From Inflammation to Oncogenesis and the Impact of Weight Loss Interventions
Mariana Souto, Tiago Cúrdia Gonçalves, José Cotter
Nutrients.2025; 17(14): 2310. CrossRef
Weight loss interventions and obesity‐associated cancers in people with type 2 diabetes and overweight/obesity: A real‐world observational study
Testimony Ipaye, Jonathan Goldney, Thomas J. Wilkinson, Francesco Zaccardi, Thomas Yates, Melanie J. Davies, Karen Brown, Dimitris Papamargaritis
Diabetes, Obesity and Metabolism.2025; 27(12): 6914. CrossRef
GLP-1 receptor agonists and cancer: current clinical evidence and translational opportunities for preclinical research
Estefania Valencia-Rincón, Rajani Rai, Vishal Chandra, Elizabeth A. Wellberg
Journal of Clinical Investigation.2025;[Epub] CrossRef
Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan
Dario Tuccinardi, Davide Masi, Mikiko Watanabe, Valeria Zanghi Buffi, Francesco De Domenico, Sabrina Berti, Valentina Cipriani, Melania Manco, Silvia Manfrini, Uberto Pagotto
Journal of Endocrinological Investigation.2025; 48(12): 2761. CrossRef
The gynecologic tumor risk related to GLP-1 receptor agonists and SGLT2 inhibitors use: a network meta-analysis of 91 randomized controlled trials
Ping-Tao Tseng, Bing-Yan Zeng, Chih-Wei Hsu, Cheuk-Kwan Sun, Mein-Woei Suen, Andre F. Carvalho, Brendon Stubbs, Yen-Wen Chen, Tien-Yu Chen, Wei-Te Lei, Po-Huang Chen, Jiann-Jy Chen, Yow-Ling Shiue, Bing-Syuan Zeng, Kuan-Pin Su, Chih-Sung Liang
Journal of Hematology & Oncology.2025;[Epub] CrossRef

Case Report

A Case of an Adrenal Hemangioma Mimicking a Pancreatic Tail Tumor.: Yun kyong Jeon, Ji Ryang Kim, Yong Seong An, Ji Hae Kwon, Yang Ho Kang, Seok Man Son, In Ju Kim, Yong Ki Kim; J Korean Endocr Soc. 2008;23(1):62-65. Published online February 1, 2008; DOI: https://doi.org/10.3803/jkes.2008.23.1.62

2,899 View
23 Download

Abstract PDF: Adrenal hemangiomas are rare non-functioning tumors that originate from the retroperitoneal organs. They are generally asymptomatic, and are usually discovered at autopsy. In 1955, Johnson and Jeppensen reported the first case of a surgically removed adrenal hemangioma. We report a case of adrenal hemangioma that mimicked a pancreatic tail tumor, as detected by computed tomography. We made a diagnosis of an adrenal hemangioma from endoscopic ultrasonography and confirmed the diagnosis following a laparascopic adrenalectomy. If one is suspicious of an adrenal hemangioma, one needs to assess the lesion from every aspect. With the advancement of diagnostic techniques in arteriography, ultrasound, and computed tomography, the frequency of preoperative recognition and diagnosis is on the increase. Still, it is difficult to diagnose an adrenal hemangioma just from an imaging study. One should consider performing surgery for removal of the tumor to rule out a malignancy, and to prevent traumatic rupture. With the case presentation, we review the clinical, radiographic, and pathological features of adrenal hemangiomas.

First
Prev
Page of 1
Next
Last

Search